pharmacovigillance

Send This

Download

Comment

Favourite

more

Rating :

Rate It:

Embed :

Khushbu on Jul 14, 2012 Says :

good presentation.

Post a comment

Post Comment on Twitter Post Comment on SlideWorld

Comments:

Subscribe to follow-up comments

Notes

Hide Notes

Slide 1 :

Pharmacovigilance Dr. SURENDRA.S.AKASH MD

Slide 2 :

Pharmacovigilance The science and activities relating to the detection, evaluation, understanding and prevention of adverse drug reactions or any other drug-related problems

Slide 3 :

Aims of Pharmacovigilance To improve patient care and safety To improve public health and safety To contribute to the assessment of benefit, harm, effectiveness and risk of medicines To promote understanding, education and clinical training

Slide 4 :

Who are the partners? Government Industry Hospitals and academia Medical and pharmaceutical associations Poisons information centres Health professionals Patients Consumers Media WHO

Slide 5 :

History 1986 - a formal adverse drug reaction (ADR) monitoring system consisting of 12 regional centers, each covering a population of 50 million, was proposed for India. In 1989, under the aegis of the Drug Controller of India, six regional centres were set up in Mumbai, New Delhi, Calcutta, Lucknow, Pondicherry and Chandigarh.

Slide 6 :

In 1997, India joined the WHO Programme for International Drug Monitoring managed by the Uppsala Monitoring Centre, Sweden. Of the six centres, only the centres in Mumbai and New Delhi were active, yet spontaneous reporting of ADRs was poor.

Slide 7 :

History Recognising the need for improved ADR monitoring in India, the Government of India sent a proposal to the World Bank for funding. The World Bank approved the proposal with an annual grant of $US 0.1 million for 5 years and the National Pharmacovigilance programme was launched in November 2004.

Slide 8 :

Why do we need pharmacovigilance?

Slide 9 :

1959 / 61– Epidemia de focomelia por Talidomida (4.000 – 10.000 casos no mundo, com 15% de mortos)

Slide 10 :

Reason 1: Humanitarian concern – Insufficient evidence of safety from clinical trials Animal experiments Phase 1 – 3 studies prior to marketing authorization

Slide 11 :

Examples of product recalls due to toxicity

Slide 12 :

Reason 2 Medicines are supposed to save lives Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. Lepakhin V. Geneva 2005

Slide 13 :

More than 3% of all deaths seem to be caused by adverse reactions to medical drugs, according to new research.

Slide 14 :

Warfarin, Insulin and Digoxin are the most Dangerous drugs in the elderly. Do we believe that?

Slide 15 :

Reason 3 ADRs are expensive !! 6.5% of admissions are due to ADRs

Slide 16 :

Cost of ADRs in the US? Cost of drug related morbidity and mortality exceeded $177.4 billion in 2000 (Ernst FR & Grizzle AJ, 2001: J American Pharm. Assoc) ADR related cost to the country exceeds the cost of the medications themselves

Slide 17 :

Reason 4: Promoting rational use of medicines and adherence

Slide 18 :

Prescription problems

Slide 19 :

Reason 5 Ensuring public confidence

Slide 20 :

Slide 21 :

Slide 22 :

Slide 23 :

According to a fact sheet by WHO(May-2010) about the rational use of medicines ,more than 50 percent of all medicines are not correctly prescribed ,dispensed, and sold: and more than 50 percent patients take their drugs incorrectly.

Slide 24 :

Reason 6 Ethics To know of something that is harmful to another person who does not know, and not telling, is unethical

Slide 25 :

Not reporting a serious unknown reaction is unethical valid for everyone patient health professional manufacturer authorities

Slide 26 :

ADR FORM

Slide 27 :

ADR FORM

Slide 28 :

What to report? The programme particularly solicits reports of: ? All adverse events suspected to have been caused by new drugs and ?drugs of current interest' (List published by CDSCO {Central Drugs Standard Control Organization} from time to time)

Slide 29 :

? Reactions to any other drugs which are suspected of significantly affecting a patient's management, including reactions suspected of causing: ? Death ? Life-threatening (real risk of dying) ? Hospitalization (initial or prolonged) ? Disability (significant, persistent or permanent) ? Congenital anomaly ? Required intervention to prevent permanent impairment or damage.

Slide 30 :

WHO Programme for International Drug Monitoring

Slide 31 :

National PVig Programme

Slide 32 :

BLDE college KLE belgaum AIIMS newdelhi UMC Sweden WHO-HQ Geneva Ministry of Health India

Slide 33 :

SO….WHAT IS OUR ROLE? SEND NOT ONLY QUANTITY BUT….

Slide 34 :

HOW? Monitor clinical status of patients Identify the correct ADRs not side effects Get more information Investigate at hospital level Help practitioners to fill-up the forms Keep patient’s record if more information needed

Slide 35 :

CONCLUSION Pharmacovigilance looks at all available information to assess the safety profile of a drug. Pharmacovigilance should also take the benefit of the drug in account. Pharmacovigilance is required for systematically identifying and correlating drugs and side-effects and taking corrective actions, especially for the product launching first time in India.

Slide 36 :

THANKYOU

Slide 37 :

Tegaserod is reported to increase the risk of heart attacks by 10 times, while the use of gatifloxacin in elderly patients may increase risk of developing serious hyperglycemia 17 times compared with other anti-biotics

Free Powerpoint Templates

	surendraakash 10 Months ago.



336 Views, 0 favourite
pharmacovigillance-efforts unlimited
More By User Flag as inappropriate Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details. Cancel